StockData
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc (PTGX) stock

PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)

Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –

Protagonist Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Protagonist Therapeutics's price to sales ratio was 30.9× on Nov 11, 2026, against 26.9× a year earlier. Over the last 5 years it ranged from 5.2× to 143.3×, with a median of 24.2×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202630.9×+4.9
2025Dec 31, 202526.1×+19.0
2024Dec 31, 20247.1×−34.9
2023Apr 28, 202342.0×+26.7
2022Dec 30, 202215.3×−51.6
2021Dec 31, 202166.8×+55.0
2019Jul 31, 201911.9×+7.8
2018Dec 31, 20184.1×–

More Protagonist Therapeutics figures

See a number that looks wrong?